{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:03:47Z","timestamp":1792688627754,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114456","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T13:53:47Z","timestamp":1742651627000},"page":"114456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Understanding the pleiotropic effects of CXCL10\/IP-10 in the immunopathogenesis of inflammatory rheumatic diseases: Implications for better understanding disease mechanisms"],"prefix":"10.1016","volume":"153","author":[{"given":"Mohsen","family":"Rokni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Khomeijani-Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2025.114456_bb0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000357780","article-title":"The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis","volume":"21","author":"Vazirinejad","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.intimp.2025.114456_bb0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10753-012-9555-1","article-title":"CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus","volume":"36","author":"Ahmadi","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2025.114456_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis","volume":"13","author":"Rabquer","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/jsrd.5000226","article-title":"Angiostatic and angiogenic chemokines in systemic sclerosis: an overview","volume":"2","author":"Bellando Randone","year":"2017","journal-title":"J. Scleroderma and Related Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.114456_bb0025","article-title":"Salirasib inhibits the expression of genes involved in fibrosis in fibroblasts of systemic sclerosis patients, immunity","volume":"12","author":"Sadeghi Shaker","year":"2024","journal-title":"Inflammation Dis."},{"key":"10.1016\/j.intimp.2025.114456_bb0030","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2017","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114456_bb0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41584-019-0323-6","article-title":"Chemokines in rheumatic diseases: pathogenic role and therapeutic implications","volume":"15","author":"Miyabe","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2025.114456_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/893106","article-title":"The multifaceted functions of CXCL10 in cardiovascular disease","volume":"2014","author":"van den Borne","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.intimp.2025.114456_bb0045","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1002\/art.30573","article-title":"CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis","volume":"63","author":"Laragione","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2025.114456_bb0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41366-018-0102-5","article-title":"Upregulation of angiostatic chemokines IP-10\/CXCL10 and I-TAC\/CXCL11 in human obesity and their implication for adipose tissue angiogenesis","volume":"42","author":"Hueso","year":"2018","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1353-6","article-title":"Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis","volume":"19","author":"Lee","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2025.114456_bb0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines\u2014chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114456_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114456_bb0070","doi-asserted-by":"crossref","first-page":"6194864","DOI":"10.1155\/2020\/6194864","article-title":"Role of chemokine (C-X-C motif) ligand 10 (CXCL10) in renal diseases","volume":"2020","author":"Gao","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"4","key":"10.1016\/j.intimp.2025.114456_bb0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2567.2010.03384.x","article-title":"Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes","volume":"132","author":"Korniejewska","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2025.114456_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fmed.2018.00271","article-title":"The role of CXCR3 and its chemokine ligands in skin disease and Cancer","volume":"5","author":"Kuo","year":"2018","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114456_bb0085","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.intimp.2025.114456_bb0090","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41419-023-06354-2","article-title":"The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches","volume":"14","author":"Chan","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdsr.2020.07.002","article-title":"Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma","volume":"56","author":"Shetty","year":"2020","journal-title":"The Japanese dental Sci. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2025.114456_bb0100","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/ar1997","article-title":"Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies","volume":"8","author":"Proost","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1189\/jlb.5A0717-302","article-title":"A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines","volume":"102","author":"Zhao","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114456_bb0110","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20112142","article-title":"Macrophages induce differentiation of plasma cells through CXCL10\/IP-10","volume":"209","author":"Xu","year":"2012","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.114456_bb0115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1189\/jlb.2MR0915-441R","article-title":"Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets","volume":"99","author":"Karin","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0120","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1210\/en.2006-1639","article-title":"Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes","volume":"148","author":"Kanda","year":"2007","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.intimp.2025.114456_bb0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.it.2004.02.006","article-title":"CXC chemokines: the regulatory link between inflammation and angiogenesis","volume":"25","author":"Romagnani","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2025.114456_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106393","article-title":"Hormesis: wound healing and keratinocytes","volume":"183","author":"Calabrese","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.intimp.2025.114456_bb0135","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.4049\/jimmunol.163.10.5686","article-title":"IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis","volume":"163","author":"Keane","year":"1999","journal-title":"J. Immunol."},{"issue":"43","key":"10.1016\/j.intimp.2025.114456_bb0140","doi-asserted-by":"crossref","first-page":"33549","DOI":"10.1074\/jbc.M110.123604","article-title":"M-Calpain activation is regulated by its membrane localization and by its binding to phosphatidylinositol 4,5-bisphosphate","volume":"285","author":"Leloup","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12931-018-0834-8","article-title":"Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology","volume":"19","author":"Rout-Pitt","year":"2018","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.114456_bb0150","first-page":"2824","article-title":"CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma","volume":"9","author":"Ren","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.114456_bb0155","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.7150\/ijbs.61350","article-title":"TNF-\u03b1 augments CXCL10\/CXCR3 axis activity to induce epithelial-mesenchymal transition in colon cancer cell","volume":"17","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1183\/09031936.00068411","article-title":"Dimethylfumarate inhibits CXCL10 via haem oxygenase-1 in airway smooth muscle","volume":"41","author":"Seidel","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.intimp.2025.114456_bb0165","first-page":"197","article-title":"Interferon-\u03b3 induces Interleukin-6 production and alpha-smooth muscle actin expression in systemic sclerosis fibroblasts","volume":"23","author":"Rokni","year":"2024","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2025.114456_bb0170","series-title":"Biology of Bone and Cartilage, Genetics of bone biology and skeletal disease","first-page":"173","author":"Boyce","year":"2018"},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0175","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.23372","article-title":"Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis","volume":"58","author":"Kwak","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2025.114456_bb0180","article-title":"Macrophage-osteoclast associations: origin","volume":"12","author":"Sun","year":"2021","journal-title":"Polarization, and Subgroups, Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-017-1353-6","article-title":"Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis","volume":"19","author":"Lee","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.114456_bb0190","doi-asserted-by":"crossref","first-page":"1048505","DOI":"10.3389\/fimmu.2022.1048505","article-title":"The osteoblast secretome in Staphylococcus aureus osteomyelitis","volume":"13","author":"Granata","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114456_bb0195","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ja.2011.64","article-title":"Ganodermycin, a novel inhibitor of CXCL10 expression from Ganoderma applanatum","volume":"64","author":"Jung","year":"2011","journal-title":"J. Antibiot."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","article-title":"The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications","volume":"24","author":"Rokni","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.114456_bb0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00011-017-1106-7","article-title":"Increased frequencies of circulating CXCL10-, CXCL8-and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients","volume":"67","author":"Carvalheiro","year":"2018","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.berh.2012.01.011","article-title":"Scleroderma\u2013New aspects in pathogenesis and treatment","volume":"26","author":"Balbir-Gurman","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"17","key":"10.1016\/j.intimp.2025.114456_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710150","article-title":"The prostacyclin analogue Iloprost modulates CXCL10 in systemic sclerosis","volume":"23","author":"Colasanti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114456_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-010-1610-4","article-title":"Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis","volume":"30","author":"Hasegawa","year":"2011","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114456_bb0225","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/annrheumdis-2012-202814","article-title":"Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin","volume":"73","author":"Mathes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2025.114456_bb0230","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.3390\/ijms22062894","article-title":"Muscle damage in systemic sclerosis and CXCL10: the potential therapeutic role of PDE5 inhibition","volume":"22","author":"Corinaldesi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114456_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104883","article-title":"High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies","volume":"98","author":"Al-Adwi","year":"2023","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.intimp.2025.114456_bb0240","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reumae.2023.12.005","article-title":"CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis","volume":"20","author":"Makarem","year":"2024","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"4","key":"10.1016\/j.intimp.2025.114456_bb0250","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1165\/rcmb.2004-0175OC","article-title":"Inhibition of pulmonary fibrosis by the chemokine IP-10\/CXCL10","volume":"31","author":"Tager","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114456_bb0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1152\/physiolgenomics.00158.2013","article-title":"The wound healing, chronic fibrosis, and cancer progression triad","volume":"46","author":"Rybinski","year":"2014","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.intimp.2025.114456_bb0260","doi-asserted-by":"crossref","first-page":"1151246","DOI":"10.3389\/fimmu.2023.1151246","article-title":"Ras family signaling pathway in immunopathogenesis of inflammatory rheumatic diseases","volume":"14","author":"Sadeghi Shaker","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1224-1","article-title":"Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker","volume":"19","author":"Pandya","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114456_bb0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejr.2019.06.002","article-title":"Predictive significance of CXCL8, CXCL10 and CXCL16 in juvenile idiopathic and rheumatoid arthritis Iraqi patients","volume":"42","author":"Muhsin","year":"2020","journal-title":"The Egyptian Rheumatologist"},{"issue":"null","key":"10.1016\/j.intimp.2025.114456_bb0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S243636","article-title":"Role of chemokines and chemokine receptors in rheumatoid arthritis","volume":"9","author":"Elemam","year":"2020","journal-title":"ImmunoTargets and Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2025.114456_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3385","article-title":"Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis","volume":"13","author":"Lee","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0285","doi-asserted-by":"crossref","first-page":"9993","DOI":"10.1038\/s41598-018-28404-y","article-title":"Upregulation of chemokine CXCL10 enhances chronic pulmonary inflammation in tree shrew collagen-induced arthritis","volume":"8","author":"Gao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114456_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109395","article-title":"CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17\/Treg cell balance","volume":"64","author":"Bakheet","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2025.114456_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110099","article-title":"CXCR3 antagonist NBI-74330 mitigates joint inflammation in collagen-induced arthritis model in DBA\/1J mice","volume":"118","author":"Ahmad","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1666-0","article-title":"Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations","volume":"20","author":"Reynolds","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/1756-185X.13808","article-title":"Association between COX-2 and 15-PGDH polymorphisms and SLE susceptibility","volume":"23","author":"Sandoughi","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0310","first-page":"4067","article-title":"Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0315","article-title":"Relationship between prolactin rs1341239 gene polymorphism and prolactin serum level in Iranian patients with systemic lupus erythematosus","volume":"6","author":"Rokni","year":"2023","journal-title":"J. Zabol Med. School."},{"issue":"5","key":"10.1016\/j.intimp.2025.114456_bb0320","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/BOR.0000000000000318","article-title":"Environmental exposures and the development of systemic lupus erythematosus","volume":"28","author":"Barbhaiya","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42358-023-00345-9","article-title":"Evaluation of Core Decompression Outcome in Systemic Lupus Erythematosus with Hip Osteonecrosis: A Retrospective Cohort Study","volume":"vol. 64","author":"Hadighi","year":"2024","journal-title":"Adv. Rheumatol. (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.114456_bb0335","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12016-013-8403-x","article-title":"Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review","volume":"47","author":"Kuhn","year":"2014","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0340","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/ar4451","article-title":"Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset","volume":"16","author":"Dominguez-Gutierrez","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2025.114456_bb0345","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cyto.2016.01.012","article-title":"Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis","volume":"81","author":"Wang","year":"2016","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.intimp.2025.114456_bb0350","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1600-6143.2004.00525.x","article-title":"High pretransplant serum levels of CXCL10\/IP-10 are related to increased risk of renal allograft failure","volume":"4","author":"Rotondi","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2025.114456_bb0355","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/cei.12655","article-title":"The exaggerated inflammatory response in Beh\u00e7et's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-\u03b3\/CXCL10 IP-10 pathway","volume":"181","author":"Ambrose","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114456_bb0360","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet\u2019s disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0365","doi-asserted-by":"crossref","first-page":"14720","DOI":"10.1038\/s41598-017-15189-9","article-title":"CXCL10\/CXCR3 axis is associated with disease activity and the development of mucocutaneous lesions in patients with Beh\u00e7et\u2019s disease","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.114456_bb0370","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114456_bb0375","doi-asserted-by":"crossref","first-page":"14720","DOI":"10.1038\/s41598-017-15189-9","article-title":"CXCL10\/CXCR3 axis is associated with disease activity and the development of mucocutaneous lesions in patients with Beh\u00e7et\u2019s disease","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925004461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925004461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:48:34Z","timestamp":1762552114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925004461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":75,"alternative-id":["S1567576925004461"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114456","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the pleiotropic effects of CXCL10\/IP-10 in the immunopathogenesis of inflammatory rheumatic diseases: Implications for better understanding disease mechanisms","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114456"}}